Browse PLA2G4B

Summary
SymbolPLA2G4B
Namephospholipase A2, group IVB (cytosolic)
Aliases Phospholipase A2 group IVB; Cytosolic phospholipase A2 beta
Chromosomal Location15q11.2-q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm, cytosol ; SUBCELLULAR LOCATION: Isoform 3: Mitochondrion membrane; Peripheral membrane protein. Early endosome membrane; Peripheral membrane protein. Note=Translocates to membrane vesicles in a calcium-dependent fashion.
Domain PF00168 C2 domain
PF01735 Lysophospholipase catalytic domain
Function

Calcium-dependent phospholipase A2 that selectively hydrolyzes glycerophospholipids in the sn-2 position with a preference for arachidonoyl phospholipids. Has a much weaker activity than PLA2G4A. Isoform 3 has calcium-dependent activity against palmitoyl-arachidonyl-phosphatidylethanolamine and low level lysophospholipase activity but no activity against phosphatidylcholine. Isoform 5 does have activity against phosphatidylcholine.

> Gene Ontology
 
Biological Process GO:0001676 long-chain fatty acid metabolic process
GO:0006575 cellular modified amino acid metabolic process
GO:0006631 fatty acid metabolic process
GO:0006644 phospholipid metabolic process
GO:0006650 glycerophospholipid metabolic process
GO:0006654 phosphatidic acid biosynthetic process
GO:0006658 phosphatidylserine metabolic process
GO:0006690 icosanoid metabolic process
GO:0006986 response to unfolded protein
GO:0007567 parturition
GO:0009395 phospholipid catabolic process
GO:0016042 lipid catabolic process
GO:0019369 arachidonic acid metabolic process
GO:0019722 calcium-mediated signaling
GO:0019932 second-messenger-mediated signaling
GO:0030968 endoplasmic reticulum unfolded protein response
GO:0033559 unsaturated fatty acid metabolic process
GO:0034620 cellular response to unfolded protein
GO:0034976 response to endoplasmic reticulum stress
GO:0035966 response to topologically incorrect protein
GO:0035967 cellular response to topologically incorrect protein
GO:0036148 phosphatidylglycerol acyl-chain remodeling
GO:0036150 phosphatidylserine acyl-chain remodeling
GO:0036151 phosphatidylcholine acyl-chain remodeling
GO:0036152 phosphatidylethanolamine acyl-chain remodeling
GO:0036498 IRE1-mediated unfolded protein response
GO:0044242 cellular lipid catabolic process
GO:0044706 multi-multicellular organism process
GO:0046434 organophosphate catabolic process
GO:0046470 phosphatidylcholine metabolic process
GO:0046471 phosphatidylglycerol metabolic process
GO:0046473 phosphatidic acid metabolic process
GO:0046475 glycerophospholipid catabolic process
GO:0046486 glycerolipid metabolic process
GO:0046503 glycerolipid catabolic process
GO:0097164 ammonium ion metabolic process
Molecular Function GO:0004620 phospholipase activity
GO:0004622 lysophospholipase activity
GO:0004623 phospholipase A2 activity
GO:0005543 phospholipid binding
GO:0005544 calcium-dependent phospholipid binding
GO:0008970 phosphatidylcholine 1-acylhydrolase activity
GO:0016298 lipase activity
GO:0047498 calcium-dependent phospholipase A2 activity
GO:0052689 carboxylic ester hydrolase activity
Cellular Component GO:0005743 mitochondrial inner membrane
GO:0005769 early endosome
GO:0010008 endosome membrane
GO:0031901 early endosome membrane
GO:0044440 endosomal part
> KEGG and Reactome Pathway
 
KEGG hsa04010 MAPK signaling pathway
hsa04014 Ras signaling pathway
hsa04270 Vascular smooth muscle contraction
hsa04370 VEGF signaling pathway
hsa04611 Platelet activation
hsa04664 Fc epsilon RI signaling pathway
hsa04666 Fc gamma R-mediated phagocytosis
hsa04724 Glutamatergic synapse
hsa04726 Serotonergic synapse
hsa04730 Long-term depression
hsa04750 Inflammatory mediator regulation of TRP channels
hsa04912 GnRH signaling pathway
hsa04913 Ovarian steroidogenesis
hsa04921 Oxytocin signaling pathway
hsa00564 Glycerophospholipid metabolism
hsa00565 Ether lipid metabolism
hsa00590 Arachidonic acid metabolism
hsa00591 Linoleic acid metabolism
hsa00592 alpha-Linolenic acid metabolism
hsa01100 Metabolic pathways
Reactome R-HSA-1482788: Acyl chain remodelling of PC
R-HSA-1482839: Acyl chain remodelling of PE
R-HSA-1482925: Acyl chain remodelling of PG
R-HSA-1482801: Acyl chain remodelling of PS
R-HSA-1483206: Glycerophospholipid biosynthesis
R-HSA-1483115: Hydrolysis of LPC
R-HSA-381070: IRE1alpha activates chaperones
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-392499: Metabolism of proteins
R-HSA-1483257: Phospholipid metabolism
R-HSA-1483166: Synthesis of PA
R-HSA-381119: Unfolded Protein Response (UPR)
R-HSA-381038: XBP1(S) activates chaperone genes
Summary
SymbolPLA2G4B
Namephospholipase A2, group IVB (cytosolic)
Aliases Phospholipase A2 group IVB; Cytosolic phospholipase A2 beta
Chromosomal Location15q11.2-q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PLA2G4B and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolPLA2G4B
Namephospholipase A2, group IVB (cytosolic)
Aliases Phospholipase A2 group IVB; Cytosolic phospholipase A2 beta
Chromosomal Location15q11.2-q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PLA2G4B in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.6 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolPLA2G4B
Namephospholipase A2, group IVB (cytosolic)
Aliases Phospholipase A2 group IVB; Cytosolic phospholipase A2 beta
Chromosomal Location15q11.2-q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PLA2G4B in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.140.792
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.3030.762
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.4620.579
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.3020.579
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.0120.995
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.6560.773
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.5170.211
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.5630.449
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.5610.517
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.440.196
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 283.6250.00527
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2050.317
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PLA2G4B in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91622.26.2160.53
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 592011.18.91
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPLA2G4B
Namephospholipase A2, group IVB (cytosolic)
Aliases Phospholipase A2 group IVB; Cytosolic phospholipase A2 beta
Chromosomal Location15q11.2-q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PLA2G4B. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPLA2G4B
Namephospholipase A2, group IVB (cytosolic)
Aliases Phospholipase A2 group IVB; Cytosolic phospholipase A2 beta
Chromosomal Location15q11.2-q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PLA2G4B. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PLA2G4B.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPLA2G4B
Namephospholipase A2, group IVB (cytosolic)
Aliases Phospholipase A2 group IVB; Cytosolic phospholipase A2 beta
Chromosomal Location15q11.2-q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PLA2G4B. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPLA2G4B
Namephospholipase A2, group IVB (cytosolic)
Aliases Phospholipase A2 group IVB; Cytosolic phospholipase A2 beta
Chromosomal Location15q11.2-q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PLA2G4B expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPLA2G4B
Namephospholipase A2, group IVB (cytosolic)
Aliases Phospholipase A2 group IVB; Cytosolic phospholipase A2 beta
Chromosomal Location15q11.2-q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PLA2G4B and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPLA2G4B
Namephospholipase A2, group IVB (cytosolic)
Aliases Phospholipase A2 group IVB; Cytosolic phospholipase A2 beta
Chromosomal Location15q11.2-q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PLA2G4B collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.